Chemical activators of transmembrane protein 150B can engage in distinct biochemical signaling pathways that lead to the functional activation of the protein. Forskolin is a diterpene that serves as an activator of adenylate cyclase, which catalyzes the conversion of ATP to cAMP. This increase in intracellular cAMP levels can activate transmembrane protein 150B through cAMP-dependent mechanisms. Similarly, IBMX, a non-selective phosphodiesterase (PDE) inhibitor, raises cAMP and cGMP levels, which in turn can activate transmembrane protein 150B by enhancing the signaling through these secondary messengers. Additionally, various PDE inhibitors such as Sildenafil, Vardenafil, and Tadalafil specifically target PDE5, augmenting cGMP levels within cells. The elevation of cGMP can trigger the activation of transmembrane protein 150B through cGMP-dependent protein kinases. Cilostazol and Anagrelide, both PDE3 inhibitors, also elevate cAMP levels that can lead to the activation of transmembrane protein 150B via cAMP-dependent signaling pathways.
In the same vein, Papaverine, a non-specific PDE inhibitor, boosts both cAMP and cGMP concentrations, which can activate transmembrane protein 150B through either cAMP or cGMP-dependent routes. Rolipram, by selectively inhibiting PDE4, leads to an accumulation of cAMP, which can then activate transmembrane protein 150B through pathways regulated by cAMP. Vinpocetine and Zaprinast, inhibitors of PDE1 and PDE5 respectively, result in the enhancement of both cAMP and cGMP levels, which can activate transmembrane protein 150B through a variety of signal transduction pathways. Lastly, Milrinone, another selective PDE3 inhibitor, increases cAMP concentration, thereby enabling the activation of transmembrane protein 150B through cAMP-linked signaling networks. Each chemical, through its unique action on different PDEs, contributes to the regulation of intracellular messenger levels, thereby influencing the activity of transmembrane protein 150B through direct interactions with the cAMP or cGMP signaling pathways that are integral to cellular responses.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Directly activates adenylate cyclase leading to increased cAMP levels which can activate transmembrane protein 150B by cAMP-dependent pathways. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
Non-selective inhibitor of phosphodiesterases which increases levels of cAMP and cGMP, possibly leading to the activation of transmembrane protein 150B via secondary messengers. | ||||||
Cilostazol | 73963-72-1 | sc-201182 sc-201182A | 10 mg 50 mg | $107.00 $316.00 | 3 | |
Inhibits phosphodiesterase type 3 (PDE3) increasing cAMP levels which can activate transmembrane protein 150B through cAMP-mediated signaling pathways. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $516.00 $720.00 $16326.00 | 7 | |
Inhibits PDE5, leading to increased cGMP levels which can activate transmembrane protein 150B through cGMP-dependent signaling mechanisms. | ||||||
Tadalafil | 171596-29-5 | sc-208412 | 50 mg | $176.00 | 13 | |
Inhibits PDE5, increasing cGMP concentration which can activate transmembrane protein 150B via cGMP-dependent protein kinases. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $147.00 | ||
Inhibits PDE3, resulting in elevated cAMP levels which can activate transmembrane protein 150B through cAMP-dependent pathways. | ||||||
Papaverine | 58-74-2 | sc-279951 sc-279951A sc-279951B | 10 mg 50 mg 100 mg | $153.00 $265.00 $459.00 | ||
Non-selective PDE inhibitor, increases cAMP and cGMP levels, which can activate transmembrane protein 150B via cAMP or cGMP-dependent pathways. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $75.00 $212.00 | 18 | |
Selective PDE4 inhibitor, increases cAMP levels which can activate transmembrane protein 150B through cAMP-regulated signaling pathways. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Inhibits PDE1, leading to increased cAMP and cGMP levels which can activate transmembrane protein 150B through multiple signaling pathways. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $103.00 $245.00 | 8 | |
Inhibits PDE5, increasing cGMP levels which can activate transmembrane protein 150B through cGMP-dependent signaling pathways. |